Shanghai Tangrun Pharmaceuticals

Shanghai Tangrun Pharmaceuticals is a clinical-stage biotechnology company specializing in the discovery and development of next-generation therapies for metabolic disorders. The company's primary focus is on multi-targeting peptide drugs that act on the GLP-1, GIP, and glucagon receptors to treat obesity, type 2 diabetes, and metabolic-associated steatohepatitis (MASH). Its lead program, TRM-201, is a dual GLP-1/GIP receptor agonist currently undergoing clinical evaluation for weight management and glycemic control. Tangrun is supported by leading venture capital firms, including Qiming Venture Partners and Lilly Asia Ventures, and aims to provide more effective and tolerable treatment options for the global metabolic disease market. The company leverages advanced peptide engineering to optimize the pharmacological profiles of its candidates for improved patient outcomes.